Lexeo Therapeutics (LXEO) Long-Term Investments (2025 - 2026)
Lexeo Therapeutics recorded quarterly Long-Term Investments of $3.4 million in Q1 2026, little changed quarter-over-quarter from $3.4 million in Q4 2025, and down 51.81% year-over-year from $7.0 million in Q1 2025.
Lexeo Therapeutics' Long-Term Investments history runs 2 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- In Q1 2026, Long-Term Investments fell 51.81% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $3.4 million (down 51.81% YoY), while the FY2025 annual figure was $3.4 million, changed N/A from the prior year.
- Long-Term Investments came in at $3.4 million for Q1 2026 at Lexeo Therapeutics, roughly flat from $3.4 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $7.0 million in Q1 2025 to a low of $3.4 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | 3.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.39 Mn |
| Dec 31, 2025 | 3.39 Mn |
| Sep 30, 2025 | 3.39 Mn |
| Jun 30, 2025 | 3.39 Mn |
| Mar 31, 2025 | 7.04 Mn |